These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36781562)

  • 1. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
    Kim S; Seok HY
    Neurol Sci; 2023 Jun; 44(6):1841-1848. PubMed ID: 36781562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
    Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
    Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination.
    Francis AG; Elhadd K; Camera V; Ferreira Dos Santos M; Rocchi C; Adib-Samii P; Athwal B; Attfield K; Barritt A; Craner M; Fisniku L; Iversen AKN; Leach O; Matthews L; Redmond I; O'Riordan J; Scalfari A; Tanasescu R; Wren D; Huda S; Leite MI; Fugger L; Palace J
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
    Dinoto A; Sechi E; Ferrari S; Gajofatto A; Orlandi R; Solla P; Maccabeo A; Maniscalco GT; Andreone V; Sartori A; Manganotti P; Rasia S; Capra R; Mancinelli CR; Mariotto S
    Mult Scler Relat Disord; 2022 Feb; 58():103424. PubMed ID: 35216793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
    Paybast S; Emami A; Baghalha F; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Sep; 65():103960. PubMed ID: 35763914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.
    Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M
    Front Immunol; 2023; 14():1106472. PubMed ID: 36761740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
    Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
    Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
    Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
    Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
    Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
    Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
    Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios.
    Carnero Contentti E; Rojas JI; Criniti J; Lopez PA; Daccach Marques V; Soto de Castillo I; Tkachuk V; Marrodan M; Correale J; Farez MF; Kim HJ; Hyun JW; Messina S; Mariano R; Rocca MA; Cacciaguerra L; Filippi M; Palace J; Juryńczyk M
    Mult Scler Relat Disord; 2022 May; 61():103778. PubMed ID: 35452969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD).
    Diem L; Hammer H; Hoepner R; Pistor M; Remlinger J; Salmen A
    Int Rev Neurobiol; 2022; 164():129-178. PubMed ID: 36038203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
    Yeo T; Siew RWE; Gulam MY; Tye JSN; Aw AYY; Sivalingam T; Peng X; Yong KP; Saffari SE; Chao Y; Tan K
    J Neurol; 2023 Jun; 270(6):2817-2825. PubMed ID: 37027019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.